Skip to main content
Premium Trial:

Request an Annual Quote

Microbiome Firm Intus Bio Acquires Bioinformatics Company Pattern Genomics

NEW YORK — Microbiome research firm Intus Biosciences said on Wednesday that it has acquired Pattern Genomics, a developer of genome analysis software.

Financial and other terms of the deal were not disclosed. It was supported by Connecticut Innovations, an investor in both companies.

Farmington, Connecticut-based Intus Bio has developed a platform, dubbed Titan-1, that combines unspecified patented assays and proprietary analysis tools to generate high-resolution, strain-level bacterial microbiome data for clinical and environmental applications. Intus Bio said the acquisition of Groton, Connecticut-based Pattern Genomics will provide it with additional machine learning tools for biomarker discovery and patient stratification across large datasets and populations.

The two companies, which have previously collaborated, will together have "an unmatched ability to produce and analyze high-resolution bacterial data at scale, creating incredible opportunities across every aspect of healthcare," Intus Bio CEO Paul Denslow said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.